India, April 28 -- Jagsonpal Pharmaceuticals, a niche player in the domestic pharmaceutical space, has delivered a combination of stable financial performance and strong capital return initiatives. The company's board has recommended a Rs. 4 per share dividend (200% payout) and approved a buyback of up to 16 lakh shares, signaling confidence in its financial position.

As of April 2026, Jagsonpal Pharmaceuticals shares are trading at Rs. 206, with a market capitalization of Rs. 1,383 crore and today the shares went up to 4.92% as compared to their previous close of Rs. 203. The stock has recorded a 52-week high of Rs. 302 and a low of Rs. 155, indicating notable volatility over the past year. The company trades at a P/E ratio of 31.0, re...